Current Report Filing (8-k)
July 08 2022 - 4:06PM
Edgar (US Regulatory)
0001602078
false
0001602078
2022-07-01
2022-07-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report (Date of earliest event
reported): July 1,
2022
NEMAURA MEDICAL INC.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
001-38355 |
|
46-5027260 |
(Commission File Number) |
|
(IRS Employer Identification No.) |
57 West 57th Street
Manhattan, NY |
10019 |
(Address of principal executive offices) |
(Zip Code) |
|
|
|
Registrant’s telephone number, including area code: |
+1 (646) 416-8000 |
N/A
(Former name or former
address, if changed since last report) |
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
NMRD |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective
July 1, 2022, Justin Mclarney was terminated as Chief Financial Officer of Nemaura Medical, Inc. (the “Company”). The Company
has commenced a search for a U.S.-based replacement Chief Financial Officer. In
the meantime, the Company’s finance team, which has significant experience with the Company, will continue to support the Company
with respect to its accounting and financial reporting requirements, and Dewan Fazlul Hoque Chowdhury, Chief Executive Officer, President,
member of the Board of Directors and significant stockholder of the Company, will act as principal financial officer and principal accounting
officer of the Company.
Dr.
Chowdhury, age 49, has been the Company’s President, Chief Executive Officer and a member of the Company’s board of directors
since the incorporation of Dermal Diagnostics Limited (“DDL”), an indirect wholly owned subsidiary of the Company, on January
20, 2009. He is in charge of research and development of the Company’s core technologies, product development, innovation and commercialization.
He also coordinates and oversees legal compliance; development of the Company’s mission; and policy and planning. Prior to establishing
the Company, Dr. Chowdhury was the founder and CEO of Microneedle Technologies and Nemaura Pharma Limited. Dr. Chowdhury has been responsible
for negotiating commercial deals for pharmaceuticals and diagnostic devices. Additionally, he is involved in commercial negotiations
and global strategy development.
Dr. Chowdhury
originally trained as a pharmaceutical scientist and has an MSc in Microsystems and Nanotechnology and med-tech from Cranfield
University, and a Doctorate from the University of Oxford on nano-drug delivery. His experience in the pharmaceutical and med-tech
industry includes product development; manufacturing; and technical and corporate management.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit No. |
|
Description |
|
|
104 |
|
Cover Page Interactive Data File - the cover page XBRL tags are embedded
with the Inline XBRL document |
SIGNATURE
Pursuant to the requirements of
the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NEMAURA MEDICAL INC. |
|
|
|
By: |
/s/ Dewan F. H. Chowdhury |
|
|
Dewan F. H. Chowdhury Chief Executive Officer |
Date:
July 8, 2022
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024